ESBC
ZNTL icon

E.S. Barr & Co’s Zentalis Pharmaceuticals ZNTL Stock Holding History

E.S. Barr & Co’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$257K Buy
110,000
+52,500
+91% +$136K 0.02% 99
2025
Q4 		$77.6K Buy
57,500
+17,500
+44% +$25.5K ﹤0.01% 132
2025
Q3 		$60.4K Hold
40,000
– – ﹤0.01% 114
2025
Q2 		$46.4K Hold
40,000
– – ﹤0.01% 116
2025
Q1 		$63.6K Buy
+40,000
New +$86.3K ﹤0.01% 104

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

E.S. Barr & Co's ZNTL Position: Q1 2026 in Review

E.S. Barr & Co increased its Zentalis Pharmaceuticals (ZNTL) stake by 91% in Q1 2026, buying an estimated $136K and bringing the position to 110,000 shares worth $257K. The position accounts for 0.02% of the portfolio, ranked #99.

E.S. Barr & Co first reported a position in ZNTL in Q1 2025 and has held it in 5 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • E.S. Barr & Co held 110,000 shares of Zentalis Pharmaceuticals worth $257K as of Q1 2026.
  • E.S. Barr & Co bought 52,500 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $136K.
  • Zentalis Pharmaceuticals made up 0.02% of E.S. Barr & Co's portfolio in Q1 2026, its #99 holding.
  • E.S. Barr & Co first reported a position in Zentalis Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on E.S. Barr & Co's 13F filing for Q1 2026, filed 13 May 2026.